Adrenergic alpha-2 Receptor Agonists
"Adrenergic alpha-2 Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS.
| Descriptor ID |
D058647
|
| MeSH Number(s) |
D27.505.519.625.050.100.100.200 D27.505.696.577.050.100.100.200
|
| Concept/Terms |
Adrenergic alpha-2 Receptor Agonists- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha 2 Receptor Agonists
- Adrenergic alpha2-Agonists
- Adrenergic alpha2 Agonists
- alpha2-Agonists, Adrenergic
- Adrenergic alpha-2 Agonists
- Adrenergic alpha 2 Agonists
- Agonists, Adrenergic alpha-2
- alpha-2 Agonists, Adrenergic
- Adrenergic alpha-2 Receptor Agonist
- Adrenergic alpha 2 Receptor Agonist
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic alpha-2 Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic alpha-2 Receptor Agonists".
This graph shows the total number of publications written about "Adrenergic alpha-2 Receptor Agonists" by people in this website by year, and whether "Adrenergic alpha-2 Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic alpha-2 Receptor Agonists" by people in Profiles.
-
Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo-controlled crossover laboratory study. Am J Addict. 2025 Jan; 34(1):7-14.
-
The effect of dexmedetomidine on renal function after surgery: A systematic review and meta-analysis. J Clin Pharm Ther. 2022 Mar; 47(3):287-297.
-
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics. 2020 10; 17(4):1681-1693.
-
Treatment of tics associated with Tourette syndrome. J Neural Transm (Vienna). 2020 05; 127(5):843-850.
-
Use of Guanfacine for Cannabis Use Disorder and Related Symptomology. Am J Addict. 2019 11; 28(6):455-464.
-
Upcoming Therapies for Age-related Macular Degeneration. Int Ophthalmol Clin. 2019; 59(1):155-171.
-
Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br J Anaesth. 2018 Jan; 120(1):188-196.
-
Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study. J Neuropsychiatry Clin Neurosci. 2018; 30(1):66-76.
-
Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017 May 15; 376:129-132.
-
Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017 Jan 15; 372:57-59.